Domain Therapeutics Doses First Patients in Phase I / II Trial of DT-7012 Targeting CCR8 in Solid Tumors
DT-7012 is a proprietary, differentiated Treg-depleting anti-CCR8 monoclonal antibody
Differentiated binding capacities and competitive properties position it as a promising therapeutic to boost anti-tumor immunity, overcoming immunosuppression
Strasbourg, France – Montreal, Canada – Boston, United States, October 28, 2025: Domain Therapeutics ( “Domain” or “the Company” ), the GPCR experts harnessing deep receptor biology to develop breakthrough treatments for patients, today announced that the first patients have been dosed in its Phase I / II DOMISOL clinical study of DT-7012, a differentiated Treg-depleting anti-CCR8 monoclonal antibody for the treatment of solid tumors.
